

**Methylaluminum complexes based on tridentate
2,6-bis(mercaptoalkyl)pyridine SNS-ligands**

Andrey I. Fedulin, Andrei V. Churakov and Kirill V. Zaitsev

Table of content

Experimental Section

Experimental Details	S4
Synthesis of thiiranes	
Ethylene sulfide	S4
2,2-Dimethylthiirane.....	S4
2,2-Dibenzylthiirane.....	S4
1-Thiaspiro[2.5]octane.....	S5
Cyclohexene sulfide.....	S5
Synthesis of <u>SNS</u>-ligands by thiirane ring-opening by nucleophiles	
<u>Stage 1. Synthesis of substituted 2,6-methylpyridines, 2,6-MePy(CH₂CHR¹CR²R³SH) (1a-e)</u>	
<i>General procedure</i>	S5
2,6-MePy(CH ₂ CH ₂ CH ₂ SH) (1a).....	S5
2,6-MePy(CH ₂ CH ₂ CMe ₂ SH) (1b).....	S6
2,6-MePy(CH ₂ CH ₂ CBn ₂ SH) (1c).....	S6
2,6-MePy(CH ₂ CH ₂ C[CH ₂] ₅ SH) (1d).....	S6
<i>trans</i> -2,6-MePy(CH ₂ -1,2-CH[CH ₂] ₄ CHSH) (1e).....	S6
<u>Stage 2. Synthesis of the target <u>SNS</u>-ligands, 2,6-Py(CH₂CHR¹CR²R³SH)₂ (2a-e)</u>	
<i>General procedure</i>	S6
2,6-Py(CH ₂ CH ₂ CH ₂ SH) ₂ (2a).....	S7
2,6-Py(CH ₂ CH ₂ CMe ₂ SH) ₂ (2b).....	S7
2,6-Py(CH ₂ CH ₂ CBn ₂ SH) ₂ (2c).....	S7
2,6-Py(CH ₂ CH ₂ C[CH ₂] ₅ SH) ₂ (2d).....	S7
<i>trans</i> -, <i>trans</i> -2,6-Py(CH ₂ -1,2-CH[CH ₂] ₄ CHSH) ₂ (2e).....	S8

**Synthesis of Methylaluminum Complexes (3a-e)
Based on 2,6-Bis(mercaptoalkyl)pyridine *S*_N*S*-Ligands**

General Procedure	S8
[2,6-Py(CH ₂ CH ₂ CH ₂ S) ₂]AlMe (3a).....	S8
[2,6-Py(CH ₂ CH ₂ CMe ₂ S) ₂]AlMe (3b).....	S8
[2,6-Py(CH ₂ CH ₂ CBn ₂ S) ₂]AlMe (3c).....	S9
[2,6-Py(CH ₂ CH ₂ C(CH ₂) ₅ S) ₂]AlMe (3d).....	S9
[<i>trans</i> -, <i>trans</i> -2,6-Py(CH ₂ -1,2-CH(CH ₂) ₄ CHS) ₂]AlMe (3e)	S9
Ring-opening polymerization of ε-caprolactone	S9

Crystallographic Data

Experimental Details	S10
Table S1. Crystallographic Data for Compound 2,6-Py(CH ₂ CH ₂ CBn ₂ SH) ₂ (2c).....	S10

**Action of methylaluminum complexes 3c and 3d as initiators
in ring-opening polymerization of ε-caprolactone**

Table S2. Catalytic activity of methylaluminum complexes 3c and 3d in ROP of CL.....	S11
---	-----

NMR Spectra of compounds obtained

Fig. S1. ¹ H NMR spectrum (CDCl ₃ , RT) of ethylene sulfide, <i>cyclo</i> -[CH ₂ CH ₂ S].....	S12
Fig. S2. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,2-dimethylthiirane, <i>cyclo</i> -[Me ₂ CCH ₂ S].....	S12
Fig. S3. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,2-dimethylthiirane, <i>cyclo</i> -[Me ₂ CCH ₂ S].....	S13
Fig. S4. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,2-dibenzylthiirane, <i>cyclo</i> -[Bn ₂ CCH ₂ O].....	S13
Fig. S5. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,2-dibenzylthiirane, <i>cyclo</i> -[Bn ₂ CCH ₂ O].....	S14
Fig. S6. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,2-dibenzylthiirane, <i>cyclo</i> -[Bn ₂ CCH ₂ S].....	S14
Fig. S7. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,2-dibenzylthiirane, <i>cyclo</i> -[Bn ₂ CCH ₂ S].....	S15
Fig. S8. ¹ H NMR spectrum (CDCl ₃ , RT) of 1-thiaspiro[2.5]octane, <i>cyclo</i> -[(CH ₂) ₅ CCH ₂ S].....	S15
Fig. S9. ¹³ C NMR spectrum (CDCl ₃ , RT) of 1-thiaspiro[2.5]octane, <i>cyclo</i> -[(CH ₂) ₅ CCH ₂ S].....	S16
Fig. S10. ¹ H NMR spectrum (CDCl ₃ , RT) of cyclohexene sulfide, <i>cyclo</i> -[(CH ₂) ₄ CHCHS].....	S16
Fig. S11. ¹³ C NMR spectrum (CDCl ₃ , RT) of cyclohexene sulfide, <i>cyclo</i> -[(CH ₂) ₄ CHCHS].....	S17
Fig. S12. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ CH ₂ SH) (1a).....	S17
Fig. S13. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ CH ₂ SH) (1a).....	S18
Fig. S14. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ CMe ₂ SH) (1b).....	S18
Fig. S15. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ CMe ₂ SH) (1b).....	S19
Fig. S16. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ CBn ₂ SH) (1c).....	S19
Fig. S17. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ CBn ₂ SH) (1c).....	S20
Fig. S18. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ C[CH ₂] ₅ SH) (1d).....	S20
Fig. S19. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,6-MePy(CH ₂ CH ₂ C[CH ₂] ₅ SH) (1d).....	S21
Fig. S20. ¹ H NMR spectrum (CDCl ₃ , RT) of <i>trans</i> -2,6-MePy(CH ₂ -1,2-CH[CH ₂] ₄ CHSH) (1e).....	S21
Fig. S21. ¹³ C NMR spectrum (CDCl ₃ , RT) of <i>trans</i> -2,6-MePy(CH ₂ -1,2-CH[CH ₂] ₄ CHSH) (1e).....	S22
Fig. S22. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,6-Py(CH ₂ CH ₂ CH ₂ SH) ₂ (2a).....	S22
Fig. S23. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,6-Py(CH ₂ CH ₂ CH ₂ SH) ₂ (2a).....	S23
Fig. S24. ¹ H NMR spectrum (CDCl ₃ , RT) of 2,6-Py(CH ₂ CH ₂ CMe ₂ SH) ₂ (2b).....	S23
Fig. S25. ¹³ C NMR spectrum (CDCl ₃ , RT) of 2,6-Py(CH ₂ CH ₂ CMe ₂ SH) ₂ (2b).....	S24

Fig. S26. ^1H NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{CBn}_2\text{SH}$) $_2$ (2c).....	S24
Fig. S27. ^{13}C NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{CBn}_2\text{SH}$) $_2$ (2c).....	S25
Fig. S28. ^1H NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{C}(\text{CH}_2)_5\text{SH}$) $_2$ (2d).....	S25
Fig. S29. ^{13}C NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{C}(\text{CH}_2)_5\text{SH}$) $_2$ (2d).....	S26
Fig. S30. ^1H NMR spectrum (CDCl_3 , RT) of <i>trans,trans</i> -2,6-Py(CH_2 -1,2-CH[CH_2] $_4$ CHSH) $_2$ (2e).....	S26
Fig. S31. ^{13}C NMR spectrum (CDCl_3 , RT) of <i>trans,trans</i> -2,6-Py(CH_2 -1,2-CH[CH_2] $_4$ CHSH) $_2$ (2e).....	S27
Fig. S32. ^1H NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CH}_2\text{S}$) $_2$]AlMe (3a).....	S27
Fig. S33. ^{13}C NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CH}_2\text{S}$) $_2$]AlMe (3a).....	S28
Fig. S34. ^1H NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CMe}_2\text{S}$) $_2$]AlMe (3b).....	S28
Fig. S35. ^{13}C NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CMe}_2\text{S}$) $_2$]AlMe (3b).....	S29
Fig. S36. ^{27}Al NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CMe}_2\text{S}$) $_2$]AlMe (3b).....	S29
Fig. S37. ^1H NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CBn}_2\text{S}$) $_2$]AlMe (3c).....	S30
Fig. S38. ^{13}C NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CBn}_2\text{S}$) $_2$]AlMe (3c).....	S30
Fig. S39. ^{27}Al NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{CBn}_2\text{S}$) $_2$]AlMe (3c).....	S31
Fig. S40. ^1H NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{C}(\text{CH}_2)_5\text{S}$) $_2$]AlMe (3d).....	S31
Fig. S41. ^{13}C NMR spectrum (CDCl_3 , RT) of [2,6-Py($\text{CH}_2\text{CH}_2\text{C}(\text{CH}_2)_5\text{S}$) $_2$]AlMe (3d).....	S32
Fig. S42. ^1H NMR spectrum (CDCl_3 , RT) of [<i>trans,trans</i> -2,6-Py(CH_2 -1,2-CH(CH_2) $_4$ CHS) $_2$]AlMe (3e).....	S32
Fig. S43. ^{13}C NMR spectrum (CDCl_3 , RT) of [<i>trans,trans</i> -2,6-Py(CH_2 -1,2-CH(CH_2) $_4$ CHS) $_2$]AlMe (3e).....	S33
Fig. S44. ^{27}Al NMR spectrum (CDCl_3 , RT) of [<i>trans,trans</i> -2,6-Py(CH_2 -1,2-CH(CH_2) $_4$ CHS) $_2$]AlMe (3e).....	S33

References	S34
-------------------------	-----

Experimental Section

Experimental Details. All operations were conducted in a dry argon atmosphere using standard Schlenk techniques. NMR spectra, ^1H NMR (400.130 MHz), ^{13}C NMR (100.613 MHz) and ^{27}Al (104.26 MHz) spectra, were recorded on Bruker 400 or Agilent 400 spectrometers at 295 K. Chemical shifts in the spectra are given in ppm relative to internal Me_4Si (for ^1H , ^{13}C NMR) or external $[\text{Al}(\text{H}_2\text{O})_6]^{3+}$ (aqueous $\text{Al}_2(\text{SO}_4)_3$) (for ^{27}Al NMR) standards. In ^{27}Al spectra the broad background signal at 75 ppm is appeared due to NMR tube glass which may be removed using subtracting procedure. Elemental analyses were carried out using PerkinElmer® 2400 Series II CHN Elemental Analyzer in N.D. Zelinsky IOC RAS (Moscow, Russia) or Heraeus Vario Elementar EL apparatus in Graz University of Technology (Graz, Austria). Mass spectra (EI-MS, 70 eV) were recorded on a quadrupole mass spectrometer FINNIGAN MAT INCOS 50 with direct insertion; all assignments were made with reference to the most abundant isotopes. Flash chromatography was performed on SiO_2 (0.015-0.040 mm).

Size exclusion chromatography (SEC) was performed on a Agilent 1200 apparatus with Nucleogel GPC LM-5, 300/7.7 column and one precolumn (PL gel 5 μm guard) thermostated at 30 °C. The detection was achieved by differential refractometer. Tetrahydrofuran (THF) was eluted at a flow rate of 1.0 ml min^{-1} . The calculation of molar mass and polydispersity was based on polystyrene standards (Polymer Labs, Germany).

Solvents were dried using usual procedures. Tetrahydrofuran, diethyl ether were stored over solid KOH and then distilled over sodium/benzophenone. DMSO was refluxed over CaH_2 and then distilled in vacuum. Toluene and *n*-hexane were refluxed and distilled over sodium. Dichloromethane was distilled under CaH_2 ; CDCl_3 was distilled over CaH_2 under argon.

n-BuLi ('Aldrich', 2.5 M solution in hexane), AlMe_3 (2.0 M solution in toluene), isobutylene oxide, cyclohexene oxide, KSCN were the commercial reagents and were used as received. 2,6-Lutidine ('Aldrich') was distilled from KOH before using. Benzyl alcohol and ϵ -caprolactone were refluxed and distilled over CaH_2 in vacuum. Dibenzyl ketone was distilled before using.

Oxiranes were synthesized by literature procedures (1-oxaspiro[2.5]octane, *cyclo*- $[(\text{CH}_2)_5\text{CCH}_2\text{O}]$ ^[S11]); thiiranes were obtained by known methods (ethylene sulfide, *cyclo*- $[\text{CH}_2\text{CH}_2\text{S}]$ ^[S2]; 2,2-dimethylthiirane, *cyclo*- $[\text{Me}_2\text{CCH}_2\text{S}]$ ^[S3]; 2,2-dibenzylthiirane, *cyclo*- $[\text{Bn}_2\text{CCH}_2\text{S}]$ ^[S4]; cyclohexene sulfide, *cyclo*- $[(\text{CH}_2)_4\text{CHCHS}]$ ^[S5]). Known compounds $\text{Me}_3\text{SO}^+\text{I}^-$ ^[S6] were obtained using literature procedure.

Synthesis of thiiranes

Ethylene sulfide, *cyclo*- $[\text{CH}_2\text{CH}_2\text{S}]$. Obtained using literature procedure from ethylenecarbonate and KSCN.^[S2] Yellow liquid; yield 66 %.

^1H NMR (δ , ppm, CDCl_3): 2.37 (s, 4H, 2 CH_2).


^{13}C NMR (δ , ppm, CDCl_3): 18.5 (CH_2).



2,2-Dimethylthiirane, *cyclo*- $[\text{Me}_2\text{CCH}_2\text{S}]$. Obtained using literature procedure from isobutylene oxide and KSCN in water.^[S3] Yellowish liquid, b.p. 84-86 °C. Yield 95 %.

^1H NMR (δ , ppm, CDCl_3): 1.60 (s, 6H, 2Me); 2.38 (s, 2H, CH_2).

^{13}C NMR (δ , ppm, CDCl_3): 28.4 (Me); 35.3 (CH_2S); 42.4 (Me_2CS).




2,2-Dibenzylthiirane, *cyclo*- $[\text{Bn}_2\text{CCH}_2\text{S}]$.

1) Stage I. Synthesis of 2,2-dibenzylloxirane, *cyclo*- $[\text{Bn}_2\text{CCH}_2\text{O}]$. The procedure of Corey-Chaykovsky was used.^[S1, 6]

Under argon atmosphere, solid $\text{Me}_3\text{SO}^+\text{I}^-$ (7.39 g, 33.30 mmol) was added portionwise to the suspension of NaH (0.62 g, 26.00 mmol) in DMSO (50 mL) (*Warning! Hydrogen gas evolution is observed!*). The mixture was stirred for 30 min, then solution of dibenzyl ketone (5.05 g, 24.00 mmol) in DMSO was added dropwise for 5 min. The mixture was stirred for 15 min, then it was heated at 60 °C. After cooling to room temperature water (300 mL) was added, the mixture was extracted with ether (3x50 mL). The organic phase was washed with brine (10x50 mL), water (2x50 mL), dried over MgSO_4 . Then all volatile materials were removed at reduced pressure at room temperature giving 2,2-dibenzylloxirane (5.02 g, 93 %) as orange oil.

^1H NMR (δ , ppm, CDCl_3): 2.60 (s, 2H, CH_2O); 2.83, 2.89 (2d, $^2J_{\text{H-H}} = 14.4$ Hz, each 2H, CH_2Ph); 7.19-7.24 (m, 4H, Ph_H), 7.26-7.34 (m, 6H, Ph_H).



^{13}C NMR (δ , ppm, CDCl_3): 40.2 (CH_2Ph); 51.2 (CH_2O); 59.9 (Bn_2C); 126.6 ($p\text{-PhC}$), 128.3, 129.7 ($m\text{-}$ and $o\text{-PhC}$), 136.8 ($ipso\text{-PhC}$).

Anal. Calcd. for $\text{C}_{16}\text{H}_{16}\text{O}$ (M_w 224.2976): C 85.68, H 7.19. Found: C 85.54, H 7.04.

2) Stage 2. Synthesis of 2,2-dibenzylthiirane, *cyclo*-[$\text{Bn}_2\text{CCH}_2\text{S}$]. Detailed procedure is given.

2,2-Dibenzylloxirane (4.46 g, 20.00 mmol) was added to a solution of KSCN (3.50 g, 36.00 mmol) in EtOH/water (20:5 ml). The mixture was heated at 60 °C for 20 h. Then all volatile materials were removed under reduced pressure, water (20 ml) was added, and the mixture was extracted with CH_2Cl_2 (3x10 ml). The organic phase was dried over MgSO_4 , the solvent was removed in vacuum. After flash-chromatography (SiO_2 , petroleum ether/EtOAc 20:1, R_f 0.4) *cyclo*-[$\text{Bn}_2\text{CCH}_2\text{S}$] (3.14 g, 65 %) was isolated as yellow viscous oil.

^1H NMR (δ , ppm, CDCl_3): 2.54 (s, 2H, CH_2S); 2.93, 3.03 (2d, $^2J_{\text{H-H}} = 14.5$ Hz, each 2H, CH_2Ph); 7.20-7.25 (m, 4H, Ph_H), 7.26-7.33 (m, 6H, Ph_H).

^{13}C NMR (δ , ppm, CDCl_3): 31.8 (CH_2S); 43.9 (CH_2Ph); 49.6 (Bn_2CS); 126.7 ($p\text{-PhC}$), 128.2, 129.7 ($m\text{-}$ and $o\text{-PhC}$), 138.0 ($ipso\text{-PhC}$).

NMR spectra correspond to literature data.^[S4]

1-Thiaspiro[2.5]octane, *cyclo*-[(CH_2) $_5\text{CCH}_2\text{S}$].

1-Oxaspiro[2.5]octane, *cyclo*-[(CH_2) $_5\text{CCH}_2\text{O}$] (8.04 g, 72.00 mmol), was added to a solution of KSCN (16.00 g, 165.00 mmol) in water (15 ml). The two-phase mixture obtained was heated at 50 °C for 30 h. Then the aqueous phase was extracted with ether (4x20 ml), the organic phase was dried over MgSO_4 , all volatile materials were removed under reduced pressure. The residue was distilled giving *cyclo*-[(CH_2) $_5\text{CCH}_2\text{S}$] (6.07 g, 66 %) as colorless liquid with typical smell, b.p. 107-108°C/40 Torr.

^1H NMR (δ , ppm, CDCl_3): 1.37-1.43 (m, 1H, $\text{CH}(\text{H})$), 1.51-1.57 (m, 2H, CH_2), 1.61-1.71 (m, 5H, $\text{CH}(\text{H})$, 2CH_2); 1.84-1.92 (m, 2H, CH_2); 2.36 (s, 2H, CH_2S).

^{13}C NMR (δ , ppm, CDCl_3): 25.3 (6-*cyclo*-[CH_2] $_5$); 26.5 (5,5-*cyclo*-[CH_2] $_5$); 33.7 (CH_2S); 38.2 (4,4-*cyclo*-[CH_2] $_5$); 50.7 (3-*cyclo*-[CH_2] $_5$).

Anal. Calcd. for $\text{C}_7\text{H}_{12}\text{S}$ (M_w 128.2352): C 65.56, H 9.43. Found: C 65.48, H 9.56.

Cyclozene sulfide, *cyclo*-[(CH_2) $_4\text{CHCHS}$]. Obtained using literature procedure from cyclozene oxide and KSCN in water/ethanol mixture.^[S5]

^1H NMR (δ , ppm, CDCl_3): 1.19-1.30, 1.48-1.59 (2m, each 2H, 3- CH_2); 2.12-2.19 (m, 4H, 2- CH_2); 3.18-3.21 (m, 2H, 2CHS).

^{13}C NMR (δ , ppm, CDCl_3): 19.4 (3,3-*cyclo*-[CH_2] $_4$); 25.8 (2,2-*cyclo*-[CH_2] $_4$); 37.0 (CH).

Synthesis of *SNS*-ligands by thiirane ring-opening by nucleophiles





Stage 1. Synthesis of substituted 2,6-methylpyridines, 2,6-MePy($\text{CH}_2\text{CHR}^1\text{CR}^2\text{R}^3\text{SH}$) (1a-e). General procedure.

At -40 °C, a solution of *n*-BuLi (2.5 M solution in hexane, 10.00 ml, 25.00 mmol, 1.05 eq.) was added dropwise to a solution of 2,6-lutidine (2.57 g, 24.00 mmol) in THF (50 ml). The mixture was slowly warmed to room temperature for 1 h, then it was cooled to -40 °C, and the corresponding thiirane (25.00 mmol, 1.05 eq.), was added dropwise. The reaction mixture was slowly warmed to room temperature and was stirred overnight. Saturated aq. solution of NH_4Cl (50 ml) was added, the aqueous phase was extracted with CH_2Cl_2 (3x20 ml), the organic phase was dried over MgSO_4 , then all volatile materials were removed under reduced pressure.

2-(3-Mercaptopropyl)-6-methylpyridine, 2,6-MePy($\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$) (1a) was obtained using *General Procedure* from 2,6-lutidine (2.57 g, 24.00 mmol), *n*-BuLi (2.5 M solution in hexane, 10.00 mL, 25.00 mmol), ethylenesulfide, *cyclo*-[$\text{CH}_2\text{CH}_2\text{S}$] (1.50 g, 25.00 mmol) giving **1a** as colorless oil (1.88 g, 47 %) after vacuum distillation, b. p. 95-100 °C/3 mbar.

^1H NMR (δ , ppm, CDCl_3): 1.37 (t, $^3J_{\text{H-H}} = 8.0$ Hz, 1H, SH); 1.99 (quint, $^3J_{\text{H-H}} = 7.5$ Hz, 2H, $\text{CH}_2\text{CH}_2\text{SH}$); 2.48 (s, 3H, PyMe); 2.50-2.56 (m, 2H, CH_2SH); 2.81 (t, 2H, $^3J_{\text{H-H}} = 7.5$ Hz, Py CH_2); 6.88-6.94 (m, 2H, β,β' -Py H); 7.40-7.46 (m, 1H, γ -Py H).


^{13}C NMR (δ , ppm, CDCl_3): 24.1 (CH_2SH); 24.4 (PyMe); 34.1 ($\text{CH}_2\text{CH}_2\text{SH}$); 36.8 (Py CH_2); 119.6, 120.6 (β,β' -Py C); 136.5 (γ -Py C); 157.8, 160.3 (α,α' -Py C).



MS (EI, %): 167 ([M]⁺, 1); 134 ([M-SH]⁺, 15); 120 ([M-CH₂SH]⁺, 85); 107 ([M-CH₂CH₂S]⁺, 100); 92 ([PyMe]⁺, 8).

Anal. Calcd. for C₉H₁₃NS (M_w 167.2712): C 64.62, H 7.83. Found: C 64.73, H 7.92.

2-(3-Mercapto-3-methylbutyl)-6-methylpyridine, 2,6-MePy(CH₂CH₂CMe₂SH) (1b) was obtained in ether using *General Procedure* from 2,6-lutidine (2.57 g, 24.00 mmol), *n*-BuLi (2.5 M solution in hexane, 10.00 mL, 25.00 mmol) and 2,2-dimethylthiirane, *cyclo*-[CMe₂CH₂S] (2.20 g, 25.00 mmol) giving **1b** as yellow oil (2.17 g, 89 %) after flash chromatography (silica gel, petroleum ether/EtOAc 10:1, R_f 0.2).




¹H NMR (δ, ppm, CDCl₃): 1.42 (s, 6H, 2Me); 1.73 (s, 1H, SH); 1.92-1.98 (m, 2H, CH₂C); 2.49 (s, 3H, PyMe); 2.85-2.91 (m, 2H, PyCH₂); 6.90-6.96 (m, 2H, β,β'-Py_H); 7.44 (pt, ³J_{H-H} = 7.7 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 24.5 (PyMe); 32.7 (Me₂C(SH)); 34.5 (PyCH₂); 44.6 (Me₂C(SH)); 46.5 (CH₂CMe₂); 119.4, 120.4 (β,β'-Pyc); 136.5 (γ-Pyc); 157.7, 161.2 (α,α'-Pyc).

Anal. Calcd. for C₁₁H₁₇NS (M_w 195.3244): C 67.64, H 8.77. Found: C 67.74, H 8.90.

2-(3-Benzyl-3-mercapto-4-phenylbutyl)-6-methylpyridine, 2,6-MePy(CH₂CH₂CBn₂SH) (1c) was obtained in ether using *General Procedure* from 2,6-lutidine (0.81 g, 7.52 mmol), *n*-BuLi (2.5 M solution in hexane, 3.16 mL, 7.90 mmol) and 2,2-dibenzylthiirane, *cyclo*-[Bn₂CCH₂S] (1.90 g, 7.90 mmol), giving **1c** as brownish oil (2.51 g, 96 %).




¹H NMR (δ, ppm, CDCl₃): 1.44 (s, 1H, SH); 1.96-2.02 (m, 2H, CH₂C); 2.55 (s, 3H, PyMe); 3.04 (br d, ²J_{H-H} = 4.4 Hz, 4H, 2CCH₂Ph), 3.07-3.13 (m, 2H, PyCH₂); 6.90, 6.96 (2d, ³J_{H-H} = 7.6 Hz, each 1H, β,β'-Py_H); 7.25-7.37 (m, 10H, Ph_H); 7.49 (pt, ³J_{H-H} = 7.6 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 24.5 (PyMe); 33.8 (PyCH₂); 40.7 (CH₂C(SH)); 47.7 (PhCH₂); 52.1 (Bn₂C(SH)); 119.3, 120.5 (β,β'-Pyc); 126.6 (*p*-Phc); 127.8, 131.3 (*m*- and *o*-Phc); 136.6 (γ-Pyc); 137.0 (*ipso*-Phc); 157.7, 161.0 (α,α'-Pyc).

MS (EI, %): 347 ([M-H]⁺, 2); 314 ([M-SH]⁺, 48); 256 ([M-Bn]⁺, 100); 222 ([M-Bn-H₂S]⁺, 50); 120 ([M-Bn₂C(SH)]⁺, 67); 107 ([Me₂Py]⁺, 8); 91 ([Bn]⁺, 45).

Anal. Calcd. for C₂₃H₂₅NS (M_w 347.5163): C 79.49, H 7.25, N 4.03. Found: C 79.32, H 7.25, N 3.96.

2-[2-(1-Mercaptocyclohexyl)ethyl]-6-methylpyridine, 2,6-MePy(CH₂CH₂C[CH₂]₅SH) (1d) was obtained using *General Procedure* from 2,6-lutidine (0.78 g, 7.26 mmol), *n*-BuLi (2.5 M solution in hexane, 3.05 mL, 7.62 mmol) and 1-thiaspiro[2.5]octane, *cyclo*-[(CH₂)₅CCH₂S] (0.98 g, 7.62 mmol), giving **1d** as yellowish viscous oil (1.23 g, 72 %) after flash chromatography (SiO₂, petroleum ether/EtOAc 10:1, R_f 0.3).




¹H NMR (δ, ppm, CDCl₃): 1.50 (s, 1H, SH); 1.53-1.58 (m, 5H), 1.60-1.74 (m, 5H) (*cyclo*-[CH₂]₅); 1.93-2.00 (m, 2H, CH₂C); 2.50 (s, 3H, PyMe); 2.90-2.96 (m, 2H, PyCH₂); 6.93, 6.96 (2d, ³J_{H-H} = 7.6 Hz, each 1H, β,β'-Py_H); 7.45 (pt, ³J_{H-H} = 7.6 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 22.4 (3,3-*cyclo*-[CH₂]₅); 24.4 (PyMe); 25.9 (4-*cyclo*-[CH₂]₅); 33.0 (PyCH₂); 36.3 (PyCH₂CH₂); 40.0 (2,2-*cyclo*-[CH₂]₅); 49.5 (1-*cyclo*-[CH₂]₅); 119.5, 120.4 (β,β'-Pyc); 136.6 (γ-Pyc); 157.6, 161.5 (α,α'-Pyc).

MS (EI, %): 202 ([M-SH]⁺, 7); 201 ([M-H₂S]⁺, 2); 120 ([M-CySH]⁺, 100); 106 ([M-HSCyCH₂]⁺, 30).

Anal. Calcd. for C₁₄H₂₁NS (M_w 235.3882): C 71.44, H 8.99, N 5.95. Found: C 71.34, H 9.12, N 5.83.

trans-2-[(2-Mercaptocyclohexyl)methyl]-6-methylpyridine, trans-2,6-MePy(CH₂-1,2-CH[CH₂]₄CHSH) (1e) was obtained using *General Procedure* from 2,6-lutidine (2.69 g, 25.06 mmol), *n*-BuLi (2.5 M solution in hexane, 10.53 mL, 26.31 mmol, 1.05 eq.) and cyclohexane sulfide, *cyclo*-[(CH₂)₄CHCHS] (3.00 g, 26.31 mmol, 1.05 eq.), giving **1e** as yellowish viscous oil (2.33 g, 42 %) after flash chromatography (SiO₂, petroleum ether/EtOAc 10:1, R_f 0.3).




¹H NMR (δ, ppm, CDCl₃): 0.96-1.06 (m, 1H), 1.14-1.29 (m, 2H), 1.41-1.47 (m, 1H), 1.58-1.67 (m, 2H), 1.68-1.75 (m, 2H) (*cyclo*-[CH₂]₄); 1.70 (d, ²J_{H-H} = 7.0 Hz, 1H, SH); 2.08-2.16 (m, 1H, CH); 2.50 (s, 3H, PyMe); 2.47-2.59 (m, 2H, PyCH(H), CH); 3.38 (dd, ³J_{H-H} = 13.3 Hz, ²J_{H-H} = 3.9 Hz, 1H, PyCH(H)); 6.92, 6.94 (2d, ³J_{H-H} = 7.7 Hz, each 1H, β,β'-Py_H); 7.44 (pt, ³J_{H-H} = 7.7 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 24.6 (PyMe); 25.6, 26.9 (4,5-*cyclo*-[CH₂]₄); 31.6 (3-*cyclo*-[CH₂]₄); 43.1 (6-*cyclo*-[CH₂]₄); 38.6 (PyCH₂); 44.4 (CH); 46.7 (CHS); 120.4, 120.5 (β,β'-Pyc); 136.2 (γ-Pyc); 157.6, 161.1 (α,α'-Pyc).

Anal. Calcd. for C₁₃H₁₉NS (M_w 221.3617): C 70.54, H 8.65, N 6.33. Found: C 70.39, H 8.54, N 6.22.

Stage 2. Synthesis of SNS-ligands, 2,6-Py(CH₂CHR¹CR²R³SH)₂ (2a-e). General procedure. At -40 °C, a solution of *n*-BuLi (2.5 M solution in hexane, 24.43 ml, 61.07 mmol, 2.1 eq.) was added dropwise to a solution of 2,6-MePy(CH₂CHR¹CR²R³SH) (29.08 mmol) in THF (50 ml). The mixture was slowly warmed and stirred for 4 h, then it was cooled to -40 °C, and the solution of the corresponding thiirane (32.00 mmol, 1.1 eq.) in THF (20 ml) was added dropwise. The mixture was slowly warmed to room temperature and was stirred overnight. Saturated aq. solution of NH₄Cl (50 ml) was added, the aqueous phase was extracted with CH₂Cl₂ (3x20 ml), the organic phase was dried over MgSO₄, then all volatile materials were removed under reduced pressure.

2,6-Bis(3-mercaptopropyl)pyridine, 2,6-Py(CH₂CH₂CH₂SH)₂ (2a) was obtained using *General Procedure* from 2,6-MePy(CH₂CH₂CH₂SH) (**1**) (4.86 g, 29.08 mmol), *n*-BuLi (2.5 M, 24.43 ml, 61.07 mmol, 2.1 eq.) ethylenesulfide, cyclo-[CH₂CH₂S] (2.10 g, 34.90 mmol, 1.2 eq.), giving ligand **2a** as yellowish oil (4.10 g, 62 %) after vacuum distillation, bp 150-160 °C/1 Torr




¹H NMR (δ, ppm, CDCl₃): 1.41 (t, ³J_{H-H} = 8.0 Hz, 2H, 2SH); 2.01 (quint, ³J_{H-H} = 7.4 Hz, 4H, 2CH₂CH₂SH); 2.50-2.57 (m, 4H, 2CH₂SH); 2.84 (t, ³J_{H-H} = 7.6 Hz, 4H, 2CH₂Py); 6.95 (d, ³J_{H-H} = 7.7 Hz, 2H, 2β-Py_H); 7.47 (t, ³J_{H-H} = 7.7 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 24.0 (CH₂SH); 33.9 (CH₂CH₂SH); 36.6 (PyCH₂); 120.1 (β-Py_C); 136.6 (γ-Py_C); 160.4 (α-Py_C).

MS (EI, %): 227 ([M]⁺, 1); 194 ([M-SH]⁺, 12); 180 ([M-CH₂SH]⁺, 83); 160 ([M-SH-H₂S]⁺, 10); 146 ([M-CH₂SH-H₂S]⁺, 43); 133 ([M-2CH₂SH]⁺, 28); 120 ([M-C₂H₄S-CH₂SH]⁺, 100); 107 ([Me₂Py]⁺, 24).

Anal. Calcd. for C₁₁H₁₇NS₂ (M_w 227.3894): C 58.10, H 7.54, N 6.16. Found: C 57.96, H 7.58, N 6.02.

2,6-Bis(3-mercapto-3-methylbutyl)pyridine, 2,6-Py(CH₂CH₂CMe₂SH)₂ (2b) was obtained using *General Procedure* from 2,6-MePy(CH₂CH₂CMe₂SH) (**1b**) (2.10 g, 10.73 mmol), *n*-BuLi (2.5 M solution in hexane, 9.00 ml, 22.53 mmol, 2.1 eq.) and 2,2-dimethylthiirane, cyclo-[Me₂CCH₂S] (0.95 g, 10.73 mmol), giving ligand **2b** as viscous yellow oil (2.83 g, 93 %).




¹H NMR (δ, ppm, CDCl₃): 1.43 (s, 12H, 2Me₂C); 1.75 (s, 2H, 2SH); 1.94-2.00 (m, 4H, 2CH₂C); 2.87-2.93 (m, 4H, 2PyCH₂); 6.96 (d, ³J_{H-H} = 7.7 Hz, 2H, 2β-Py_H); 7.48 (t, ³J_{H-H} = 7.7 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 32.7 (Me₂C); 34.5 (PyCH₂); 44.6 (Me₂C); 46.4 (CH₂C); 119.7 (β-Py_C); 136.6 (γ-Py_C); 161.3 (α-Py_C).

MS (EI, %): 283 ([M]⁺, 2); 250 ([M-SH]⁺, 30); 216 ([M-SH-H₂S]⁺, 41); 208 ([M-Me₂CSH]⁺, 100); 174 ([M-Me₂CSH-H₂S]⁺, 80); 107 ([Me₂Py]⁺, 6).

Anal. Calcd. for C₁₅H₂₅NS₂ (M_w 283.4957): C 63.55, H 8.89. Found: C 63.55, H 8.98.

2,6-Bis(3-benzyl-3-mercapto-4-phenylbutyl)pyridine, 2,6-Py(CH₂CH₂CBn₂SH)₂ (2c) was obtained using *General Procedure* from 2,6-MePy(CH₂CH₂CBn₂SH) (**1c**) (1.84 g, 5.30 mmol), *n*-BuLi (2.5 M solution in hexane, 4.45 mL, 11.13 mmol, 2.1 eq.) and 2,2-dibenzylthiirane, cyclo-[Bn₂CCH₂S] (1.27 g, 5.30 mmol). The crude product was crystallized after treatment with *n*-hexane/ether mixture;




the solid obtained was recrystallized from minimal amount of hot *n*-hexane/CH₂Cl₂ mixture giving 2,6-Py(CH₂CH₂CBn₂SH)₂ (**2c**) (1.59 g, 51 %) as yellow powder, m. p. 132-134 °C.

¹H NMR (δ, ppm, CDCl₃): 1.45 (s, 2H, 2SH); 1.98-2.04 (m, 4H, 2CH₂C); 3.06 (br d, ²J_{H-H} = 2.2 Hz, 8H, 4CH₂Ph); 3.08-3.14 (m, 4H, 2PyCH₂); 6.92 (d, ³J_{H-H} = 7.7 Hz, 2H, 2β-Py_H); 7.22-7.35 (m, 20H, Ph_H); 7.46 (t, ³J_{H-H} = 7.7 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 33.8 (PyCH₂); 40.4 (CH₂C); 47.8 (PhCH₂); 52.2 (Bn₂C(SH)); 119.8 (β-Py_C); 126.7 (*p*-Ph_C); 127.9, 131.3 (*m*- and *o*-Ph_C); 136.6 (γ-Py_C); 137.0 (*ipso*-Ph_C); 161.0 (α-Py_C).

Anal. Calcd. for C₃₉H₄₁NS₂ (M_w 587.8795): C 79.68, H 7.03, N 2.38. Found: C 79.54, H 6.91, N 2.44.

2,6-Bis[2-(1-mercaptocyclohexyl)ethyl]pyridine, 2,6-Py(CH₂CH₂C[CH₂]₅SH)₂ (2d) was obtained using *General Procedure* from 2,6-MePy(CH₂CH₂C[CH₂]₅SH) (**1d**) (1.18 g, 5.00 mmol), *n*-BuLi (2.5 M, 4.20 ml, 10.50 mmol, 2.1 eq.) and 1-thiaspiro[2.5]octane, cyclo-[(CH₂)₅CCH₂S] (0.64 g, 5.00 mmol), giving ligand **2d** (1.55 g, 85 %) as viscous colorless oil after flash-chromatography (SiO₂, petroleum ether/EtOAc 40:1, R_f 0.2).




$^1\text{H NMR}$ (δ , ppm, CDCl_3): 1.52 (s, 2H, 2SH); 1.53-1.59 (m, 10H), 1.61-1.76 (m, 10H) (*cyclo*- $[(\text{CH}_2)_5]$); 1.95-2.01 (m, 4H, 2PyCH₂CH₂); 2.91-2.97 (m, 4H, PyCH₂CH₂); 6.97 (d, $^3J_{\text{H-H}} = 7.6$ Hz, 2H, $2\beta\text{-Py}_\text{H}$); 7.47 (t, $^3J_{\text{H-H}} = 7.6$ Hz, 1H, $\gamma\text{-Py}_\text{H}$).

$^{13}\text{C NMR}$ (δ , ppm, CDCl_3): 22.4 (3,3-*cyclo*- $[(\text{CH}_2)_5]$); 25.9 (4-*cyclo*- $[(\text{CH}_2)_5]$); 33.0 (PyCH₂); 36.3 (PyCH₂CH₂); 40.1 (2,2-*cyclo*- $[(\text{CH}_2)_5]$); 49.6 (1-*cyclo*- $[(\text{CH}_2)_5]$); 119.8 ($\beta\text{-Pyc}$); 136.6 ($\gamma\text{-Pyc}$); 161.5 ($\alpha\text{-Pyc}$).

MS (EI, %): 364 ($[\text{M}]^+$, 1); 330 ($[\text{M}-\text{H}_2\text{S}]^+$, 30); 296 ($[\text{M}-2\text{H}_2\text{S}]^+$, 33); 248 ($[\text{M}-\text{CySH}]^+$, 100); 214 ($[\text{M}-\text{CySH}-\text{H}_2\text{S}]^+$, 75); 107 ($[\text{Me}_2\text{Py}]^+$, 22).

Anal. Calcd. for $\text{C}_{21}\text{H}_{33}\text{NS}_2$ (M_w 363.6234): C 69.36, H 9.15, N 3.85. Found: C 69.38, H 9.08, N 3.77.

***trans,trans*-2,6-Bis[(2-mercaptocyclohexyl)methyl]pyridine, *trans,trans*-2,6-Py(CH₂-1,2-CH[CH₂]₄CHSH)₂ (2e)** was obtained using *General Procedure* from 2,6-MePy(CH₂-1,2-CH[CH₂]₄CHSH) (**1e**) (1.11 g, 5.03 mmol), *n*-BuLi (2.5 M solution in hexane, 4.23 mL, 10.55 mmol, 2.1 eq.) and cyclohexane sulfide, *cyclo*- $[(\text{CH}_2)_4\text{CHCHS}]$ (0.57 g, 5.03 mmol), giving ligand **2e** as viscous colorless oil (1.35 g, 80 %) after chromatography (SiO_2 , petroleum ether/EtOAc 9:1, R_f 0.4). Compound represents a mixture of two diastereomers A, B ((R^*,S^*) , $(R^*,S^*)/(R^*,S^*)$, (S^*,R^*)) in 2:1 ratio.



$^1\text{H NMR}$ (δ , ppm, CDCl_3): 0.93-1.02 (m, 2H), 1.13-1.28 (m, 4H), 1.41-1.49 (m, 2H), 1.56-1.72 (m, 8H) (*cyclo*- $[\text{CH}_2]_4$); 1.75 (d, $^3J_{\text{H-H}} = 7.1$ Hz, diastereomer B), 1.80 (d, $^3J_{\text{H-H}} = 6.9$ Hz, diastereomer A) (2H, SH); 2.07-2.13 (m, 2H, PyCH₂CH); 2.50-2.64 (m, 4H, CHS, PyC(H)H); 3.26-3.34 (m, 2H, PyC(H)H); 6.91 (d, $^3J_{\text{H-H}} = 7.6$ Hz, diastereomer A), 6.93 (d, $^3J_{\text{H-H}} = 7.7$ Hz, diastereomer B) (2H, $2\beta\text{-Py}_\text{H}$); 7.45 (t, $^3J_{\text{H-H}} = 7.6$ Hz, 1H, $\gamma\text{-Py}_\text{H}$).

$^{13}\text{C NMR}$ (δ , ppm, CDCl_3): 25.7, 26.8, 26.9 (4,5-*cyclo*- $[\text{CH}_2]_4$); 31.7 (3-*cyclo*- $[\text{CH}_2]_4$); 42.7, 42.8 (6-*cyclo*- $[\text{CH}_2]_4$); 38.4, 38.5 (PyCH₂); 44.0, 44.1 (PyCH₂CH); 46.5, 46.6 (CSH); 120.8, 120.9 ($\beta\text{-Pyc}$); 135.8 ($\gamma\text{-Pyc}$); 159.8 ($\alpha\text{-Pyc}$). Signals corresponding to the minor diastereomer B are italicized.


Anal. Calcd. for $\text{C}_{19}\text{H}_{29}\text{NS}_2$ (M_w 335.5703): C 68.00, H 8.71, N 4.7. Found: C 67.62, H 8.68, N 4.26.

Synthesis of Methylaluminum Complexes Based on 2,6-Bis(mercaptoalkyl)pyridine *SNS*-Ligands.

General Procedure

At -50 °C the solution of AlMe_3 (2.0 M in toluene, 1.00 ml, 2.00 mmol) was added dropwise to the solution of *SNS*-polydentate ligand (2.00 mmol) in toluene (20 ml). The mixture was slowly warmed to room temperature and was stirred overnight. All volatile materials were removed under reduced pressure.

[2,6-Bis(3-sulfidopropyl)pyridine]methylaluminum, [2,6-Py(CH₂CH₂CH₂S)₂]AlMe (3a) was obtained using *General Procedure* from AlMe_3 (2.0 M in toluene, 1.00 ml, 2.00 mmol) and ligand 2,6-Py(CH₂CH₂CH₂SH)₂ (**2a**) (0.4548 g, 2.00 mmol) giving complex **3a** as yellow powder (0.5134 g, 96 %).




$^1\text{H NMR}$ (δ , ppm, CDCl_3): -0.18 (s, 3H, AlMe); 2.03-2.08 (m, 4H, 2PyCH₂CH₂); 2.32-2.38, 2.78-2.84 (2m, each 2H, SCH(H)); 3.00-3.06, 3.73-3.81 (2m, each 2H, 2PyCH(H)); 7.30 (d, $^3J_{\text{H-H}} = 7.8$ Hz, 2H, $2\beta\text{-Py}_\text{H}$); 7.92 (t, $^3J_{\text{H-H}} = 7.8$ Hz, 1H, $\gamma\text{-Py}_\text{H}$).

$^{13}\text{C NMR}$ (δ , ppm, CDCl_3): 25.2 (CH₂SAl); 31.6 (CH₂); 33.8 (PyCH₂); 125.0 ($\beta\text{-Pyc}$); 142.0 ($\gamma\text{-Pyc}$); 162.8 ($\alpha\text{-Pyc}$). The signal of Al-Me was not found.

Anal. Calcd. for $\text{C}_{12}\text{H}_{18}\text{AlNS}_2$ (M_w 267.3896): C 53.90, H 6.79, N 5.24. Found: C 52.72, H 6.44, N 4.88.

[2,6-Bis(3-methyl-3-sulfidobutyl)pyridine]methylaluminum, [2,6-Py(CH₂CH₂CMe₂S)₂]AlMe (3b) was obtained using *General Procedure* from AlMe_3 (2.0 M in toluene, 1.00 ml, 2.00 mmol) and ligand 2,6-Py(CH₂CH₂CMe₂SH)₂ (**2b**) (0.5670 g, 2.00 mmol) giving complex **3b** as yellow foam (0.6082 g, 94 %).



$^1\text{H NMR}$ (δ , ppm, CDCl_3): -0.16 (s, 3H, AlMe); 1.29, 1.43 (2s, each 6H, 4Me); 1.92-1.98, 2.08-2.12 (2m, each 2H, 2PyCH₂CH₂); 3.25-3.31, 3.59-3.67 (2m, each 2H, 2PyCH₂); 7.25 (d, $^3J_{\text{H-H}} = 7.8$ Hz, 2H, $2\beta\text{-Py}_\text{H}$); 7.84 (t, $^3J_{\text{H-H}} = 7.7$ Hz, 1H, $\gamma\text{-Py}_\text{H}$).

$^{13}\text{C NMR}$ (δ , ppm, CDCl_3): 33.5, 34.0 (2Me); 35.2 (PyCH₂); 45.4 (PyCH₂CH₂); 45.8 (Me₂C); 124.5 ($\beta\text{-Pyc}$); 141.8 ($\gamma\text{-Pyc}$); 164.0 ($\alpha\text{-Pyc}$). The signal of Al-Me was not found.

$^{27}\text{Al NMR}$ (δ , ppm, CDCl_3): 153 ($\omega_{1/2} = 3100$ Hz).

Anal. Calcd. for $\text{C}_{16}\text{H}_{26}\text{AlNS}_2$ (M_w 323.4959): C 59.40, H 8.10, N 4.33. Found: C 58.62, H 7.78, N 4.12.


[2,6-Bis(3-benzyl-3-sulfido-4-phenylbutyl)pyridine]methylaluminum,
[2,6-Py(CH₂CH₂CBn₂S)₂]AlMe (3c) was obtained using *General Procedure* from AlMe₃ (2.0 M in toluene, 1.00 ml, 2.00 mmol) and ligand 2,6-Py(CH₂CH₂CBn₂SH)₂ (**2c**) (1.1758 g, 2.00 mmol) giving complex **3c** as white powder (0.5274 g, 42 %) after recrystallization from minimal amount of *n*-hexane/CH₂Cl₂ mixture.

¹H NMR (δ, ppm, CDCl₃): -0.13 (s, 3H, AlMe); 1.69-1.76, 2.04-2.12 (2m, each 2H, 2PyCH₂CH₂); 2.82-2.90 (m, 2H, PyC(H)H); 3.01, 3.16 (2br s, each 4H, 2PhCH₂); 3.46-3.52 (m, 2H, PyC(H)H); 6.76 (d, ³J_{H-H} = 7.6 Hz, 2H, β-Py_H); 7.24-7.37 (m, 20H, Ph_H); 7.59 (t, ³J_{H-H} = 7.6 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 32.8 (PyCH₂); 39.7 (PyCH₂CH₂); 49.7, 50.0 (CH₂Ph); 54.1 (Bn₂C); 124.3 (β-Py_C); 125.9, 126.3 (*p*-Ph_C); 127.4, 127.9, 131.0, 131.6 (*m*- and *o*-Ph_C); 138.3, 138.4 (*ipso*-Ph_C); 141.9 (γ-Py_C); 163.5 (α-Py_C). The signal of Al-Me was not found.

²⁷Al NMR (δ, ppm, CDCl₃): 154 (ω_{1/2} = 5900 Hz).

Anal. Calcd. for C₄₀H₄₂AlNS₂ (M_w 627.8797): C 76.52, H 6.74, N 2.23. Found: C 75.83, H 6.49, N 1.92.




[2,6-Bis[2-(1-sulfidocyclohexyl)ethyl]pyridine]methylaluminum,

[2,6-Py(CH₂CH₂C(CH₂)₅S)₂]AlMe (3d) was obtained using *General Procedure* from AlMe₃ (2.0 M in toluene, 1.00 ml, 2.00 mmol) and ligand 2,6-Py(CH₂CH₂C[CH₂]₅SH)₂ (**2d**) (0.7272 g, 2.00 mmol) giving complex **3d** as white powder (0.5247 g, 65 %) after hot recrystallization from the minimal amount of *n*-hexane/toluene mixture.

¹H NMR (δ, ppm, CDCl₃): -0.22 (s, 3H, AlMe); 1.16-1.28 (m, 4H), 1.34-1.47 (m, 6H), 1.52-1.64 (m, 6H), 1.79-1.87 (m, 4H) (*cyclo*-[CH₂]₅); 1.89-1.94, 2.10-2.17 (2m, each 2H, 2CCH₂); 3.23-3.30, 3.59-3.66 (2m, each 2H, 2PyCH₂); 7.22 (d, ³J_{H-H} = 7.8 Hz, 2H, 2β-Py_H); 7.80 (t, ³J_{H-H} = 7.8 Hz, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 22.6 (3,3-*cyclo*-[CH₂]₅); 26.2 (4-*cyclo*-[CH₂]₅); 32.3 (PyCH₂); 41.2 (PyCH₂CH₂); 42.5 (2,2-*cyclo*-[CH₂]₅); 51.0 (1-*cyclo*-[CH₂]₅); 124.3 (β-Py_C); 141.6 (γ-Py_C); 164.3 (α-Py_C). The signal of Al-Me was not found.

Anal. Calcd. for C₂₂H₃₄AlNS₂ (M_w 403.6236): C 65.47, H 8.49, N 3.47. Found: C 64.33, H 8.18, N 3.42.



[trans,trans-2,6-Bis[(2-sulfidocyclohexyl)methyl]pyridine]methylaluminum,


[trans,trans-2,6-Py(CH₂-1,2-CH(CH₂)₄CHS)₂]AlMe (3e) was obtained using *General Procedure* from AlMe₃ (2.0 M in toluene, 1.00 ml, 2.00 mmol) and ligand 2,6-Py(CH₂-1,2-CH[CH₂]₄CHSH)₂ (**2e**) (0.6711 g, 2.00 mmol) giving complex **3e** as white powder (0.7126 g, 95 %). Complex **3e** was isolated as a mixture of two diastereomers *A* and *B* ((*R*^{*},*S*^{*}), (*R*^{*},*S*^{*}))/(*S*^{*},*R*^{*}) in 2:1 ratio.

¹H NMR (δ, ppm, CDCl₃): -0.23, -0.19 (2s, 3H, AlMe; *A* and *B* diastereoisomers); 1.10-1.74 (m, 16H, *cyclo*-[CH₂]₄); 1.78-2.24 (m, 4H), 2.68-3.20 (m, 2H) (2CH, 2PyCH(H)); 3.44-3.52, 3.85-4.23 (2m, each 1H, 2SCH); 7.20-7.30 (m, 2H, 2β-Py_H); 7.81-7.88 (m, 1H, γ-Py_H).

¹³C NMR (δ, ppm, CDCl₃): 26.3, 26.4, 26.5, 26.8, 27.0, 27.1 (4,5-*cyclo*-[CH₂]₄, *A* and *B* diastereoisomers); 31.3, 32.7, 37.0 (3-*cyclo*-[CH₂]₄, *A* and *B* diastereoisomers); 38.1, 38.2, 38.5 (PyCH₂, *A* and *B* diastereoisomers); 41.6, 42.0, 42.1 (6-*cyclo*-[CH₂]₄, *A* and *B* diastereoisomers); 43.9, 45.0, 47.9 (CH, *A* and *B* diastereoisomers); 48.0, 48.2, 48.7 (SCH, *A* and *B* diastereoisomers); 125.2, 125.5, 126.1 (β-Py_C, *A* and *B* diastereoisomers); 140.4, 140.8 (γ-Py_C, *A* and *B* diastereoisomers); 159.0, 161.0, 164.7 (α-Py_C, *A* and *B* diastereoisomers). Signals corresponding to the minor diastereomer *B* are italicized. The signals of Al-Me were not found.

²⁷Al NMR (δ, ppm, CDCl₃): 156 (ω_{1/2} = 3400 Hz).

Anal. Calcd. for C₂₀H₃₀AlNS₂ (M_w 375.5704): C 63.96, H 8.05, N 3.73. Found: C 63.07, H 7.82, N 3.62.



Ring-opening polymerization of ε-caprolactone

Ring-opening polymerization in toluene solution

A toluene solution of benzyl alcohol (0.01 mmol, 1.00 M) was added to the initiator (0.01 mmol), then ε-caprolactone in toluene (1.00 M) was added. The mixture was heated in oil bath at specified temperature and time. Then MeOH (5 ml) was added, all volatile materials were removed under reduced pressure.

Ring-opening polymerization in bulk

ϵ -Caprolactone and benzyl alcohol were added to the initiator (0.01 mmol). The mixture was heated in oil bath at the specified temperature and time. The material thus obtained was dissolved in THF (10 ml) and poured into MeOH (50 ml). The polymer obtained was filtered off.

Crystallographic Data

Experimental Details. Experimental intensities were collected on a Bruker Smart Apex II diffractometer (graphite monochromatized Mo- $K\alpha$ radiation, $\lambda=0.71073$ Å) using ω -scan mode. Absorption correction based on measurements of equivalent reflections (SADABS) was applied. The structure was solved by direct methods and refined by full matrix least-squares on F^2 (Shelxtl) with anisotropic thermal parameters for all non-hydrogen atoms. All H atoms were found from difference Fourier synthesis and refined isotropically. Crystallographic data have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-2088271.

Table S1. Crystallographic Data for Compound 2,6-Py(CH₂CH₂CBn₂SH)₂ (**2c**).

empirical formula	C ₃₉ H ₄₁ NS ₂
M_w	587.85
temperature (K)	120(2)
size (mm)	0.40 x 0.25 x 0.20
cryst. system	orthorhombic
space group	<i>Pbcn</i>
a (Å)	6.4574(6)
b (Å)	17.4109(16)
c (Å)	28.481(3)
V (Å ³)	3202.1(5)
Z	4
ρ_{calc} (g cm ⁻³)	1.219
abs coeff. (mm ⁻¹)	0.195
$F(000)$	1256
θ range (deg)	2.34– 27.00
no. of collected/unique rflns.	3504 / 2848
R_{int}	0.0506
data/restraints/params.	2848 / 0 / 273
goodness of fit on F^2	1.027
final R indices ($I > 2\sigma(I)$)	$R_1 = 0.0364$, $wR_2 = 0.0859$
R indices (all data)	$R_1 = 0.0491$, $wR_2 = 0.0933$
largest diff. peak/hole (e/Å ³)	0.332 / -0.232

Action of methyl aluminum complexes **3c and **3d** as initiators in ring-opening polymerization of ϵ -caprolactone (CL)**

Table S2. Catalytic activity of methyl aluminum complexes **3c** and **3d** in ROP of CL.

initiator ^a	[CL]/[Al]	solvent	conversion, % ^c	M_n (NMR), Da ^d	M_n (calc.), Da ^e	M_n , Da ^f	M_w/M_n ^f
3c	300	- ^b	100	26000	34300	20800	1.202
3d	300	- ^b	18	3100	7900	3200	1.086
3c	200	PhCH ₃	6	600	1500	-	-
3d	200	PhCH ₃	6	800	1500	-	-

^a 100 °C; 12 h; 1 eq. of BnOH ([Al] = [BnOH]) was used

^b in bulk (without solvent)

^c obtained based on ¹H NMR spectroscopy data of crude reaction mixture

^d M_n (NMR) = I(CH₂Ph)_{PCL} × M_w (CL) + M_w (BnOH)

^e M_n (calc.) = M_w (CL) × [CL]_o/[BnOH] × (conversion) + M_w (BnOH)

^f SEC data, THF as an eluent; M_n = 0.56 × M_n (experimental)

NMR spectra of the compounds obtained




Fig. S1. ¹H NMR spectrum (CDCl₃, RT) of ethylenesulfide, *cyclo*-[CH₂CH₂S].




Fig. S2. ^1H NMR spectrum (CDCl_3 , RT) of 2,2-dimethylthiirane, *cyclo*- $[\text{Me}_2\text{CCH}_2\text{S}]$.




Fig. S3. ^{13}C NMR spectrum (CDCl_3 , RT) of 2,2-dimethylthiirane, *cyclo*- $[\text{Me}_2\text{CCH}_2\text{S}]$.




Fig. S4. ^1H NMR spectrum (CDCl_3 , RT) of 2,2-dibenzoyloxirane, *cyclo*- $[\text{Bn}_2\text{CCH}_2\text{O}]$.




Fig. S5. ^{13}C NMR spectrum (CDCl_3 , RT) of 2,2-dibenzylloxirane, *cyclo*-[$\text{Bn}_2\text{CCH}_2\text{O}$].




Fig. S6. ^1H NMR spectrum (CDCl_3 , RT) of 2,2-dibenzylthiirane, *cyclo*-[$\text{Bn}_2\text{CCH}_2\text{S}$].




Fig. S9. ^{13}C NMR spectrum (CDCl_3 , RT) of 1-thiaspiro[2.5]octane, *cyclo*- $[(\text{CH}_2)_5\text{CCH}_2\text{S}]$.




Fig. S10. ^1H NMR spectrum (CDCl_3 , RT) of cyclohexene sulfide, *cyclo*- $[(\text{CH}_2)_4\text{CHCHS}]$.




Fig. S11. ¹³C NMR spectrum (CDCl₃, RT) of cyclohexane sulfide, *cyclo*-[(CH₂)₄CHCHS].




Fig. S12. ¹H NMR spectrum (CDCl₃, RT) of 2,6-MePy(CH₂CH₂CH₂SH) (**1a**).




Fig. S13. ¹³C NMR spectrum (CDCl₃, RT) of 2,6-MePy(CH₂CH₂CH₂SH) (1a).






Fig. S14. ¹H NMR spectrum (CDCl₃, RT) of 2,6-MePy(CH₂CH₂CMe₂SH) (1b).






Fig. S17. ^{13}C NMR spectrum (CDCl_3 , RT) of 2,6-MePy($\text{CH}_2\text{CH}_2\text{CBn}_2\text{SH}$) (**1c**).






Fig. S18. ^1H NMR spectrum (CDCl_3 , RT) of 2,6-MePy($\text{CH}_2\text{CH}_2\text{C}[\text{CH}_2]_5\text{SH}$) (**1d**).






Fig. S21. ^{13}C NMR spectrum (CDCl_3 , RT) of *trans*-2,6-MePy(CH_2 -1,2-CH[CH_2] $_4$ CHSH) (1e).




Fig. S22. ^1H NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$) $_2$ (2a).




Fig. S23. ^{13}C NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$) $_2$ (**2a**).




Fig. S24. ^1H NMR spectrum (CDCl_3 , RT) of 2,6-Py($\text{CH}_2\text{CH}_2\text{CMe}_2\text{SH}$) $_2$ (**2b**).




Fig. S25. ¹³C NMR spectrum (CDCl₃, RT) of 2,6-Py(CH₂CH₂CMe₂SH)₂ (2b).






Fig. S26. ¹H NMR spectrum (CDCl₃, RT) of 2,6-Py(CH₂CH₂CBn₂SH)₂ (2c).






Fig. S31. ¹³C NMR spectrum (CDCl₃, RT) of *trans-, trans*-2,6-Py(CH₂-1,2-CH[CH₂]₄CHSH)₂ (**2e**).




Fig. S32. ¹H NMR spectrum (CDCl₃, RT) of [2,6-Py(CH₂CH₂CH₂S)₂]AlMe (**3a**).




Fig. S33. ^{13}C NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{CH}_2\text{S})_2]\text{AlMe}$ (**3a**).




Fig. S34. ^1H NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{CMe}_2\text{S})_2]\text{AlMe}$ (**3b**).




Fig. S35. ^{13}C NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{CMe}_2\text{S})_2]\text{AlMe}$ (**3b**).




Fig. S36. ^{27}Al NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{CMe}_2\text{S})_2]\text{AlMe}$ (**3b**).




Fig. S37. ¹H NMR spectrum (CDCl₃, RT) of [2,6-Py(CH₂CH₂CBn₂S)₂]AlMe (**3c**).




Fig. S38. ¹³C NMR spectrum (CDCl₃, RT) of [2,6-Py(CH₂CH₂CBn₂S)₂]AlMe (**3c**).




Fig. S39. ^{27}Al NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{CBn}_2\text{S})_2]\text{AlMe}$ (**3c**).




Fig. S40. ^1H NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{C}(\text{CH}_2)_5\text{S})_2]\text{AlMe}$ (**3d**).




Fig. S41. ^{13}C NMR spectrum (CDCl_3 , RT) of $[2,6\text{-Py}(\text{CH}_2\text{CH}_2\text{C}(\text{CH}_2)_5\text{S})_2]\text{AlMe}$ (**3d**).




Fig. S42. ^1H NMR spectrum (CDCl_3 , RT) of $[\text{trans,trans-}2,6\text{-Py}(\text{CH}_2\text{-}1,2\text{-CH}(\text{CH}_2)_4\text{CHS})_2]\text{AlMe}$ (**3e**).




Fig. S43. ^{13}C NMR spectrum (CDCl_3 , RT) of [*trans*-,*trans*-2,6-Py(CH_2 -1,2- $\text{CH}(\text{CH}_2)_4\text{CHS}$) $_2$]AlMe (**3e**).




Fig. S44. ^{27}Al NMR spectrum (CDCl_3 , RT) of [*trans*-,*trans*-2,6-Py(CH_2 -1,2- $\text{CH}(\text{CH}_2)_4\text{CHS}$) $_2$]AlMe (**3e**).

References

- [S1] E. J. Corey, M. Chaykovsky, *Org. Synth.* 1969, **49**, 78.
- [S2] S. Searles, E. F. Lutz, H. R. Hays, H. E. Mortensen, *Org. Synth.* 1962, **42**, 59.
- [S3] H. R. Snyder, J. M. Stewart, J. B. Ziegler, *J. Am. Chem. Soc.* 1947, **69**, 2672.
- [S4] J. Huang, D.-M. Du, J. Xu, *Synthesis* 2006, 315.
- [S5] E. E. Tamelen, *Org. Synth.* 1952, **32**, 39.
- [S6] E. J. Corey, M. Chaykovsky, *J. Am. Chem. Soc.* 1965, **87**, 1353.